What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

Abstract Background It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies...

Full description

Bibliographic Details
Main Authors: Andrew P. McGovern, John M. Dennis, Beverley M. Shields, Andrew T. Hattersley, Ewan R. Pearson, Angus G. Jones, On behalf of the MASTERMIND Consortium
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Medicine
Subjects:
Type 2 diabetes
Oral glucose-lowering medication
HbA1c
Addition
Switching
Continuation
Online Access:http://link.springer.com/article/10.1186/s12916-019-1307-8

Internet

http://link.springer.com/article/10.1186/s12916-019-1307-8

Similar Items